Haleon plc

Equities

HLN

GB00BMX86B70

Pharmaceuticals

Market Closed - London S.E. 11:35:21 2024-05-21 am EDT 5-day change 1st Jan Change
331.5 GBX -0.15% Intraday chart for Haleon plc +0.79% +3.06%
LockThis Alphavalue article, the European leader in independent research, is only available to subscribers .
Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!
Already a customer? Log In
Bernstein becomes more optimistic for consumer goods - Henkel upgraded DP
UK's FTSE 100 Closes Lower Amid Inflation Focus MT
GSK Sells Remaining Stake in Haleon for $1.58 Billion MT
FTSE 100 slides; Eurozone inflation steady AN
London stocks dip as global rates outlook weighs RE
GSK sells remaining Haleon stake for GBP1.25 billion AN
FTSE 100 lacklustre as Wall Street rally ends AN
London stocks lacklustre but set for weekly gains RE
Land Securities ups dividend; GSK sells Haleon stake AN
GSK Divests Remaining Haleon Stake in GBP1.25 Billion Deal MT
GSK Sells Last Haleon Shares for $1.58 Billion DJ
GSK raises $1.5 bln from sale of remaining Haleon stake RE
GSK Raises About 1.25 Bln Stg Via Haleon Stake Sale RE
GSK to Sell Remaining Haleon Stake MT
An unknown buyer completed the acquisition of 4.2% stake in Haleon plc from GSK plc for £1.2 billion. CI
GSK to Sell Remaining Stake in Haleon Valued at Around $1.27 Billion -- Update DJ
GSK intends to sell its remaining stake in Haleon RE
GSK to Sell Stake in Haleon Valued at About $1.61 Billion DJ
GSK to sell remaining holding in spin-off Haleon AN
GSK Plans to Sell 385 Million Haleon Shares MT
GSK intends to sell its entire stake in Haleon RE
GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon CI
GSK Intends To Sell About 385 Mln Shares In Haleon RE
GSK plc : Back on track Our Logo
Deutsche Bank likes TP ICAP but says sell CMC AN
Chart Haleon plc
More charts
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (27.7%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - Pain relief medicines (23.5%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - medicines for digestive health (18.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - respiratory medicines (15.4%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (14.5%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (40.2%), North America (37.1%), and Asia/Pacific (22.7%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
3.32 GBP
Average target price
3.62 GBP
Spread / Average Target
+9.04%
Consensus
  1. Stock Market
  2. Equities
  3. HLN Stock
  4. News Haleon plc
  5. Haleon: Haleon on-track to deliver healthy and steady shareholder returns
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW